1 min read|25 words
π 62% cholesterol reduction achieved with Lilly's VERV-102 gene editor in Phase 1 trials. Single-dose treatment could replace daily medications.
Read the full article on GMJ Newsroom β
Was this article helpful?
Key Finding: Eli Lilly’s Gene Editor Cuts Cholesterol 62% in First Human Trial
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.
